All In Biotech

Drug Trial Radar · NCT06307431

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

272

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Jan 8, 2028

Study completion Jun 8, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.

Conditions

  • Renal Cell Carcinoma

Interventions

  • Intismeran autogeneBiological

    IM injection

  • PembrolizumabBiological

    IV infusion

  • PlaceboBiological

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS)Time frame: up to ~43 months

Locations

63 sites in 14 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104)

    Duarte, California

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro

    Los Angeles, California

  • UCSF Medical Center at Mission Bay ( Site 0108)

    San Francisco, California

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0102)

    New Haven, Connecticut

  • Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute-GU ( Site 0101)

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center ( Site 0100)

    New York, New York

  • Duke Cancer Institute ( Site 0106)

    Durham, North Carolina

  • Abramson Cancer Center ( Site 0107)

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center ( Site 0111)

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center ( Site 0110)

    Dallas, Texas

  • Hospital Británico de Buenos Aires-Oncology ( Site 1106)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming-Alexander Fleming ( Site 1101)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 1110)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Centro Privado de RMI Rio Cuarto ( Site 1104)

    Río Cuarto, Córdoba Province, Argentina

  • Fundacion Estudios Clinicos ( Site 1111)

    Rosario, Santa Fe Province, Argentina

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 1502)

    Macquarie University, New South Wales, Australia

  • Westmead Hospital ( Site 1501)

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si

    Brisbane, Queensland, Australia

  • Fiona Stanley Hospital-Medical Oncology ( Site 1503)

    Murdoch, Western Australia, Australia

  • BC Cancer Vancouver ( Site 0005)

    Vancouver, British Columbia, Canada

  • CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 0008)

    Québec, Quebec, Canada

  • FALP-UIDO ( Site 1202)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 1205)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 1201)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 1200)

    Viña del Mar, Valparaiso, Chile

  • Hôpital Européen Georges Pompidou ( Site 0300)

    Paris, France

  • CENTRE LEON BERARD ( Site 0305)

    Lyon Cedex08, Auvergne-Rhône-Alpes, France

  • CHU Besançon ( Site 0302)

    Besançon, Doubs, France

  • Institut Claudius Regaud ( Site 0303)

    Toulouse, Haute-Garonne, France

  • Gustave Roussy ( Site 0304)

    Villejuif, Île-de-France Region, France

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0401)

    Berlin, Germany

  • Asklepios Altona-Department of Urology ( Site 0410)

    Hamburg, Germany

  • Klinikum Stuttgart - Katharinenhospital ( Site 0400)

    Stuttgart, Baden-Wurttemberg, Germany

  • klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Sit

    Munich, Bavaria, Germany

  • Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405)

    Dresden, Saxony, Germany

  • Universitätsklinikum Jena ( Site 0402)

    Jena, Thuringia, Germany

  • Azienda Ospedaliero Universitaria di Parma ( Site 0503)

    Parma, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0501)

    Rome, Lazio, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0500)

    Milan, Lombardy, Italy

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.